Loading...
Loading...
Shares of Dendreon
DNDN closed the after-hours session under $5.00 per share, following reporting wider than expected losses on Monday. The maker of Provenge announced a strategic restructuring plan designed to save $150 million annually. The plan includes the closure of it's Morris Plains, NJ manufacturing facility and the elimination of 600 jobs over the next 12 months.
Dendreon, which traded over $57.00 on the strength of its prostate cancer drug in April 2010, ended Monday's after-hours session at $4.98, down 20% from the close of $6.18.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in